furmonertinib + pemetrexed + carboplatin

Furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication and is used as chemotherapy in NSCLC and mesothelioma. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. The combination of these three drugs is being investigated as a regimen for advanced or metastatic non-small cell lung cancer, particularly in patients with EGFR mutations[1][2][5]. This combination leverages targeted inhibition of EGFR signaling by furmonertinib alongside cytotoxic effects from pemetrexed and carboplatin.